Harvard Business Review

DECEMBER 30, 2011

Organizations invest billions annually on a success curriculum known as "leadership development," which ends up leaving so much on the table. Training and development programs almost universally focus factory-like on inputs and outputs — absorb curriculum, check a box; learn a skill, advance a rung; submit to assessment, fix a problem.

Development 17

Development Biotechnology CIO Short-term 17

Harvard Business Review

OCTOBER 26, 2011

Between 2006 and 2008, more than $1 billion venture-capital dollars were channeled into startups focused on solar, wind and biofuel technologies. Despite these gloomy headlines, three developments in the sector give us hope that the revolution in clean energy production is far from dead: 1.

Energy 11

Energy Finance IPO Biotechnology 11

Harvard Business Review

MAY 1, 2014

I learned this while leading a turnaround of NPS Pharmaceuticals , a biotechnology company that now specializes in creating treatments for rare diseases. NPS had hit a rough patch in 2006. To save the 20-year-old company, I had to get it operating like a start-up. First, let me give you a little background.

Company 9

Company Pharmaceuticals Biotechnology Short-term 9

Harvard Business Review

FEBRUARY 22, 2013

Your company has just developed an amazing new product. Years of development, energy, and, of course, money have gone into it. Cephalon's IPO was in 1991, part of the second wave of biotechnology companies to sell shares to the public. He developed the next generation form of Provigil prior to the patent expiration.

Productivity 8

Productivity Products Biotechnology IPO 8